m+Medelevator.RU
← Поиск публикаций
Journal of human immunity · 2026

Tailored conditioning for hematopoietic stem cell transplantation in children with Mendelian susceptibility to mycobacterial disease: A tale of two pathways for IFN-γ and IL-12 defects.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ganesan Kavitha, Balwani Minakshi, Seshadri Nithya, Muthukumar Vijayashree, Krishnakumar Krithika, Nalla Reddy Anuraag, Krishna Vidya, Jayakumar Indira, Uppuluri Ramya, Raj Revathi

Аннотация

Mendelian susceptibility to mycobacterial disease (MSMD) is a rare group of inborn errors of immunity associated with significant morbidity due to mycobacterial infections. Hematopoietic stem cell transplantation (HSCT) is a curative option; however, persistent infections and high levels of interferon-γ (IFN-γ) create a hostile environment for stem cell proliferation and can mediate graft rejection. We describe the outcome of children with MSMD due to IFN-γ receptor and interleukin-12 (IL-12) defects who underwent HSCT in our unit from December 2015 to December 2023. We collected the data retrospectively from a review of patient charts and analyzed the outcomes. Seven children underwent eight procedures, including four with IFN-γ defects and three with IL-12 defects. The male-to-female ratio was 1.6:1, and the median age at HSCT was 4.5 years. Five received haploidentical HSCT, and two underwent matched family donor transplants; 75% used peripheral blood stem cells. IL-12-deficient cases engrafted well with fludarabine/treosulfan-based conditioning, whereas IFN-γ-deficient cases fared better with fludarabine/treosulfan/thiotepa-based conditioning due to a higher rejection risk. Acute graft-versus-host disease (GVHD) (grade 1-2, skin/gut) occurred in two children: one developed chronic liver GVHD after donor lymphocyte infusion. Cytomegalovirus reactivation occurred in four cases, which responded to ganciclovir or cidofovir. One primary graft failure was rescued with a second HSCT; one secondary graft failure led to death from invasive fungal infection. At a median follow-up of 8 years, the overall survival was 87%. One survivor has ongoing seizures, aggressive behavior, and endocrine dysfunctions requiring supportive care. HSCT is a curative option for children with MSMD. However, we need to understand gene mutation and individualize the approach to preparation and conditioning regimens to help optimize the outcome.